A PYMNTS Company

US: Impax settles part of Solodyn antitrust suit

By  |  March 11, 2018

According to Reuters, Impax Laboratories has agreed to pay US$35 million to resolve part of litigation over claims it entered into an anticompetitive deal in a patent case to delay releasing a generic version of the acne medication Solodyn.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    On Saturday, March 10, the settlement was disclosed in papers filed in federal court in Boston. It resolved part of the antitrust litigation Impax faces over Solodyn related to sales of the drug to direct purchasers such as retailers and wholesalers.

    Remaining claims, from a class of consumers and third-party insurers and cases by individual retailers like CVS Health Corp and Rite Aid Corp, are scheduled to go to trial on Monday.

    The case is among several filed in recent years targeting “pay-for-delay” settlements, in which brand-name drugmakers resolve patent lawsuits by paying generic companies to keep their products off the market for a longer period.

    Full Content: Reuters

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.